Tricida Inc (TCDA) Receives a Buy from Cowen & Co.

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Tricida Inc (TCDAResearch Report) yesterday and set a price target of $50.00. The company’s shares closed last Monday at $32.95.

According to TipRanks.com, Nadeau is a 3-star analyst with an average return of 1.4% and a 44.4% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Phasebio Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.

Currently, the analyst consensus on Tricida Inc is a Moderate Buy with an average price target of $50.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $42.80 and a one-year low of $19.43. Currently, Tricida Inc has an average volume of 183.8K.

Based on the recent corporate insider activity of 73 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TCDA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Tricida, Inc. is a pharmaceutical company, which focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease.